Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J George

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
The Prostate|August 4, 1998
Mutational analysis of the TrkA gene in prostate cancerD J George, H Suzuki, G S Bova, et al.
Clinical Toxicology|January 1, 1976
Salicylate poisoning complicated by fluid retentionA R Temple, D J George, A K Done, et al.
Urology|February 13, 2001
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancerW K Oh, D J George, K Hackmann, et al.
The Prostate|October 12, 2000
Rational basis for Trk inhibition therapy for prostate cancerA T Weeraratna, J T Arnold, D J George, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 25, 2001
PTEN polymorphism (IVS4) is not associated with risk of prostate cancerD J George, T F Shepard, J Ma, et al.
Cancer Research|May 27, 1999
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)D J George, C A Dionne, J Jani, et al.
Prostate Cancer and Prostatic Diseases|February 3, 2016
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceN Nussbaum, D J George, A P Abernethy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480D J George, S Halabi, T F Shepard, et al.
Seminars in Oncology|October 31, 2001
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary reportW K Oh, D J George, D S Kaufman, et al.
Nature Medicine|September 1, 1995
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostateJ B Nelson, S P Hedican, D J George, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
The Prostate|August 4, 1998
Mutational analysis of the TrkA gene in prostate cancerD J George, H Suzuki, G S Bova, et al.
Clinical Toxicology|January 1, 1976
Salicylate poisoning complicated by fluid retentionA R Temple, D J George, A K Done, et al.
Urology|February 13, 2001
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancerW K Oh, D J George, K Hackmann, et al.
The Prostate|October 12, 2000
Rational basis for Trk inhibition therapy for prostate cancerA T Weeraratna, J T Arnold, D J George, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 25, 2001
PTEN polymorphism (IVS4) is not associated with risk of prostate cancerD J George, T F Shepard, J Ma, et al.
Cancer Research|May 27, 1999
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)D J George, C A Dionne, J Jani, et al.
Prostate Cancer and Prostatic Diseases|February 3, 2016
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceN Nussbaum, D J George, A P Abernethy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480D J George, S Halabi, T F Shepard, et al.
Seminars in Oncology|October 31, 2001
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary reportW K Oh, D J George, D S Kaufman, et al.
Nature Medicine|September 1, 1995
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostateJ B Nelson, S P Hedican, D J George, et al.
Pageof 3